ALKOGOLSIZ YOG'LI JIGAR KASALLIGI VA 2-TUR DIABET: KONYUGATSIYA VA RIVOJLANISH BOSQICHLARI MUAMMOSI
Keywords:
По результатам анализа литературы выделено две основных теории: алиментарная и метаболическая.Abstract
Широкая распространенность неалкогольной жировой болезни печени (НАЖБП) и сахарного диабета 2 типа (СД2), а также их взаимосвязи определяет необходимость прицельного рассмотрения данной патологии с целью оптимиза- ции подходов к диагностике и лечению пациентов с НАЖБП и СД2. Являясь компонентами метаболического синдро- ма, эти два заболевания во многом имеют схожие механизмы развития и прогрессирования, синергично повышая риск неблагоприятных исходов у коморбидных пациентов. Несмотря на общность патофизиологических механизмов, актуальным остается вопрос о последовательности развития НАЖБП и СД2.
References
В Who.int [Internet]. The top 10 causes of death [cited 2020 9 Dec]. Available from: https://www.who.int/news-room/fact-sheets/detail/ the-top-10-causes-of-death
Ротберг Г.Е., ред. Метаболический синдром. — М.: МЕД-М54 пресс-информ; 2007. [Rothberg GE, ed. Metabolic syndrome. Moscow: MED-M54 press-inform; 2007. (In Russ.)].
Ланг Г.Ф. Гипертоническая болезнь. — Л.: Медгиз; 1950. [Lang GF. Hypertonic disease. Leningrad: Medgiz; 1950. (In Russ.)].
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
doi: https://doi.org/10.2337/diab.37.12.1595
D’Adamo E, Marcovecchio ML, Giannini C, et al.
The possible role of liver steatosis in defining metabolic syndrome in prepubertal children. Metabolism. 2010;59:671-676. doi: https://doi.org/10.1016/j.metabol.2009.09.012
Беленков Ю.Н., Привалова Е.В., Каплунова В.Ю.,
и др. Метаболический синдром: история развития, основные критерии диагностики // Рациональная фармакотерапия
в кардиологии. — 2018. — Т. 14. — No5. — С. 757-765.
[Belenkov YuN, Privalova EV, Kaplunova VY, et al. Metabolic Syndrome: Development of the Issue, Main Diagnostic Criteria. Rational Pharmacotherapy in Cardiology. 2018;14(5):757-764. (In Russ.)].
doi: https://doi.org/10.20996/1819-6446-2018-14-5-757-764
Лазабник Л.Б., Голованова Е.В., Туркина С.В., и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия // Экспериментальная и клиническая гастроэнтерология. — 2021. — Т. 1. — No1. — С. 4-52. [Lazebnik LB, Golovanova EV, Turkina SV, et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.)]. doi: https://doi.org/10.31146/1682-8658-ecg-185-1-4-52
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment
of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: https://doi.org/10.1002/hep.28431
Younossi ZM, Blissett D, Blissett R, et al. The economic
and clinical burden of nonalcoholic fatty liver disease
in the United States and Europe. Hepatology. 2016;64(5):1577-1586. doi: https://doi.org/10.1002/hep.28785
de Alwis NM, Day CP. Non-alcoholic fatty liver disease:
the mist gradually clears. J Hepatol. 2008;48 Suppl 1:S104-S112. doi: https://doi.org/10.1016/j.jhep.2008.01.009
Sanyal AJ; American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705-1725. doi: https://doi.org/10.1053/gast.2002.36572
Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. doi: https://doi.org/10.1053/j.gastro.2019.11.312
International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels: IDF; 2019; 176 p.
Idf.org [Internet]. One adult in ten will have diabetes by 2030. International Diabetes Federation [cited 2011 Nov 14]. Available from: http://www.idf.org/ media-events/press-releases/2011/ diabetes-atlas-5th-edition
Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793-801.
doi: https://doi.org/10.1016/j.jhep.2019.06.021
Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212-1218. doi: https://doi.org/10.2337/dc06-2247
Targher G. Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus? Hepatobiliary Surg Nutr. 2020;9(2):239-241. doi: https://doi.org/10.21037/hbsn.2019.10.21
Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes [published correction appears in Clin Gastroenterol Hepatol. 2004 Jun;2(6):522]. Clin Gastroenterol Hepatol. 2004;2(3):262-265. doi: https://doi.org/10.1016/s1542-3565(04)00014-x
Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.
Clin Gastroenterol Hepatol. 2009;7(11):1224-1229.e12292.
doi: https://doi.org/10.1016/j.cgh.2009.06.007
Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58(10):3017-3023.
doi: https://doi.org/10.1007/s10620-013-2743-5
Fracanzani AL, Valenti L, Bugianesi E, et al. Risk
of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792-798. doi: https://doi.org/10.1002/hep.22429
Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37(6):1286-1292. doi: https://doi.org/10.1053/jhep.2003.50229
Leitner DR, Frühbeck G, Yumuk V, et al. Obesity and Type 2
Diabetes: Two Diseases with a Need for Combined Treatment Strategies — EASO Can Lead the Way. Obes Facts. 2017;10(5):483-492. doi: https://doi.org/10.1159/000480525
. Wang HH, Lee DK, Liu M, Portincasa P, Wang DQ. Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome. Pediatr Gastroenterol Hepatol Nutr. 2020;23(3):189-230. doi: https://doi.org/10.5223/pghn.2020.23.3.189
Bae JC, Cho YK, Lee WY, et al. Impact of nonalcoholic fatty
liver disease on insulin resistance in relation to HbA1c levels
in nondiabetic subjects. Am J Gastroenterol. 2010;105(11):2389-2395. doi: https://doi.org/10.1038/ajg.2010.275
Dongiovanni P, Stender S, Pietrelli A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance
in nonalcoholic fatty liver. J Intern Med. 2018;283(4):356-370. doi: https://doi.org/10.1111/joim.12719
Manchanayake J, Chitturi S, Nolan C, Farrell GC. Postprandial hyperinsulinemia is universal
in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26(3):510-516. doi: https://doi.org/10.1111/j.1440-1746.2010.06528.x
Бакулин И.Г., Сандлер Ю.Г., Винницкая Е.В., и др. Сахарный диабет и неалкогольная жировая болезнь печени: грани сопряженности // Терапевтический архив. — 2017. —
Т. 89. — No2. — С. 59-65. [Bakulin IG, Sandler YuG, Vinnitskaya EV. Diabetes mellitus and nonalcoholic fatty liver disease: The verges of contingency. Terapevticheskiy Archiv. 2017;89(2):59-65 (In Russ.)]. doi: https://doi.org/10.17116/terarkh201789259-65
De Bruyne RM, Fitzpatrick E, Dhawan A. Fatty liver disease in children: eat now pay later. Hepatol Int. 2010;4(1):375-385. Published 2010
Jan 29. doi: https://doi.org/10.1007/s12072-009-9160-z
Драпкина О.М., Корнеева О.Н., Ивашкин В.Т. Терапия неалкогольного стеатогепатита при метаболическом синдроме: фокус на эссенциальные фосфолипиды // Лечащий врач. — 2010. — No2. — С. 18-24. [Drapkina OM, Korneyeva ON, Ivashkin VT. Treatment of nonalcoholic steatohepatitis and metabolic syndrome: focus on essential phospholipids]. Lechashchii vrach [Therapist]. 2010;2: 43–45. (In Russ.)].
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non- alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402.
doi: https://doi.org/10.1016/j.jhep.2015.11.004
Лавренова Е.А., Драпкина О.М. Инсулинорезистентность
при ожирении: причины и последствия // Ожирение
и метаболизм. — 2020. — Т. 17. — No1. — C. 48-55. [Lavrenova EA, Drapkina OM. Insulin resistance in obesity: pathogenesis and effects. Obesity and metabolism. 2020;17(1):48-55. (In Russ.)].
doi: https://doi.org/10.14341/omet9759
Бабенко А.Ю., Лаевская М.Ю. Неалкогольная жировая болезнь печени — взаимосвязи с метаболическим синдромом // Русский Медицинский Журнал. — 2018. — Т. 1. — NoI. — С. 34-40. [Babenko AYu, Laevskaya MYu. Non-alcoholic fatty liver disease — relationships with metabolic syndrome. Russkiy Meditsinskiy Zhurnal. 2018;1(I):34–40. (In Russ.)].
Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006;43(1):173-81.
Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450-455. doi: https://doi.org/ 10.1016/s0002-9343(99)00271-5
Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019;40(5):1367-1393. doi: https://doi.org/10.1210/er.2019-00034
Stefan N, Fritsche A, Weikert C, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008;57(10):2762-7. doi: https://doi.org/10.2337/db08-0538
Hussey SE, Liang H, Costford SR, et al. TAK-242, a small-molecule inhibitor of Toll-like receptor 4 signalling, unveils similarities and differences in lipopolysaccharide- and lipid-induced inflammation and insulin resistance in muscle cells. Biosci Rep. 2012;33(1):37-47. doi: https://doi.org/10.1042/BSR20120098
Кытикова О.Ю., Новгородцева Т.П., Денисенко Ю.К., и др. Толл- подобные рецепторы в патофизиологии ожирения // Ожирение
и метаболизм. — 2020. — Т. 17. — No1. — C. 56-63. [Kytikova OYu, Novgorodtseva TР, Denisenko YuК, Antonyuk MV, Gvozdenko TA. Toll-like receptors in the pathophysiology of obesity. Obesity and metabolism. 2020;17(1):56-63. (In Russ.)]. doi: https://doi.org/10.14341/omet10336
Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению // Русский Медицинский Журнал. — 2001. — No2. — С. 56-8. [Butrova SA. Metabolic syndrome: pathogenesis, clinical presentation, diagnosis, treatment approaches. Russkiy Meditsinskiy Zhurnal. 2001;2:56-8. (In Russ.)].
Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87(7):3023-3028. doi: https://doi.org/10.1210/jcem.87.7.8638
Valenti L, Bugianesi E, Pajvani U, Targher G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int. 2016;36(11):1563-1579. doi: https://doi.org/10.1111/liv.13185
